Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

81.81 -1.86 (-2.22%)
Streaming Delayed Price Updated: 3:47 PM EDT, Jul 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,851,021
Open 83.78
Bid (Size) 81.81 (3)
Ask (Size) 81.82 (3)
Prev. Close 83.67
Today's Range 81.30 - 84.36
52wk Range 73.31 - 129.03
Shares Outstanding 2,531,374,696
Dividend Yield 3.96%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026. 
Via Benzinga
Merck & Co Unusual Options Activity For July 15
Via Benzinga

Performance

YTD
-17.5%
-17.5%
1 Month
+1.1%
+1.1%
3 Month
+3.3%
+3.3%
6 Month
-19.0%
-19.0%
1 Year
-36.1%
-36.1%

More News

Read More
This House of Representative Just Bought Up To $30K In 3M Stock
Via Benzinga
Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic
Via Stocktwits
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?
Via Benzinga
P/E Ratio Insights for Merck & Co
Via Benzinga
Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill
From Merck & Co., Inc.
Via Business Wire
AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial
Via Benzinga
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Via Benzinga
Topics Government World Trade
MERCK & CO. INC. (NYSE:MRK) – A Strong Dividend Stock with Solid Fundamentals
Via Chartmill
2 Top Stocks Down 16% and 17% This Year to Buy and Hold
Via The Motley Fool
Topics Intellectual Property
FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health
From Merck & Co., Inc.
Via Business Wire
U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection
From Merck Sharp & Dohme
Via Business Wire
Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps
Via Benzinga
Nvidia's $4 Trillion Milestone Lifts Wall Street: What's Moving Markets Wednesday?
Via Benzinga
Topics World Trade
Explore the top gainers and losers within the S&P500 index in today's session.
Via Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verona Pharma plc (Nasdaq - VRNA), Olo Inc. (NYSE - OLO), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC)
From Brodsky & Smith LLC
Via GlobeNewswire
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Via Benzinga
Topics Intellectual Property
Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma
Via Investor's Business Daily
Topics Government
Merck To Acquire Verona For $10B In Bid To Expand Cardio-Pulmonary Pipeline
Via Stocktwits
Topics Government
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade
From Merck & Co., Inc.
Via Business Wire
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK)
Via StockStory
Topics Artificial Intelligence Intellectual Property
Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025
From Merck & Co., Inc.
Via Business Wire
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Via Investor Brand Network
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Via FinancialNewsMedia
Topics Death

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 81.81
When was Merck & Co last traded?
The last trade of Merck & Co was at 07/15/25 03:47 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 207.10B
How many shares of Merck & Co are outstanding?
Merck & Co has 207B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.